Quartz Bio | GenomeWeb

Quartz Bio

Last week, Quartz Bio said that it had been selected to provide bioinformatics support for biomarker projects conducted by the Debiopharm group, a Swiss-based biopharmaceutical company.

NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio and the Swiss Institute of Bioinformatics are working together to develop and validate MegaClust, SIB's platform for analyzing flow cytomery data, so that they can use it to provide analysis services to pharmaceutical companies.

NEW YORK (GenomeWeb News) – A group of Swiss partners today announced a collaboration to develop, use, and promote a flow cytometry data analysis platform.

Quartz Bio, a newly minted bioinformatics consultancy outfit, is hoping to make its bread and butter by offering exploratory biomarker analysis and data management services to clients in the pharmaceutical industry.

NEW YORK (GenomeWeb News) – Merck Serono, the biopharmaceutical division of Merck KGaA, today said that it has spun out a bioinformatics firm, Quartz Bio, from its Entrepreneur Partnership Program launched earlier this year.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.